Literature DB >> 24384494

Recommendations for management of patients with neuroendocrine liver metastases.

Andrea Frilling1, Irvin M Modlin2, Mark Kidd3, Christopher Russell4, Stefan Breitenstein5, Riad Salem6, Dik Kwekkeboom7, Wan-yee Lau8, Catherine Klersy9, Valerie Vilgrain10, Brian Davidson4, Mark Siegler11, Martyn Caplin12, Enrico Solcia9, Richard Schilsky13.   

Abstract

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24384494     DOI: 10.1016/S1470-2045(13)70362-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  135 in total

Review 1.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

Review 2.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 3.  Surgical management of neuroendocrine tumor-associated liver metastases: a review.

Authors:  Miu Yee Chan; Ka Wing Ma; Albert Chan
Journal:  Gland Surg       Date:  2018-02

Review 4.  Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology.

Authors:  Keita Shimata; Yasuhiko Sugawara; Taizo Hibi
Journal:  Gland Surg       Date:  2018-02

5.  Combined associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) followed by left trisectionectomy and Whipple operation for PNET.

Authors:  Ren Ji; Shi Zuo; Siyuan Qiu; Ping Li; Albert Chan; William Sharr; Chung Mau Lo
Journal:  Gland Surg       Date:  2018-02

6.  Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.

Authors:  Junho Kang; Changhoon Yoo; Hee-Sang Hwang; Seung-Mo Hong; Kyu-Pyo Kim; Sun Young Kim; Yong-Sang Hong; Tae Won Kim; Baek-Yeol Ryoo
Journal:  Invest New Drugs       Date:  2018-12-10       Impact factor: 3.850

7.  Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.

Authors:  Linda S Sher; David M Levi; Julie S Wecsler; Mary Lo; Lydia M Petrovic; Susan Groshen; Lingyun Ji; Teresa Diago Uso; A Joseph Tector; Ann S Hamilton; J Wallis Marsh; Myron E Schwartz
Journal:  J Surg Oncol       Date:  2015-07-14       Impact factor: 3.454

Review 8.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

9.  Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus.

Authors:  Marianne Pavel; Nicole Unger; Ivan Borbath; Sergio Ricci; Tsann-Long Hwang; Thomas Brechenmacher; Jinhee Park; Fabian Herbst; Jennifer L Beaumont; Oliver Bechter
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

10.  Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment.

Authors:  Liliana Chiorean; Adrian Bartos; Doris Pelau; Dana Iancu; Tudor Ciuleanu; Rares Buiga; Irinel Oancea; Angelica Mangrau; Cornel Iancu; Radu Badea
Journal:  J Med Ultrason (2001)       Date:  2014-10-25       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.